Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
MRKR
Stock Latest News
Ratings
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
1M ago
MRKR
Premium
Company Announcements
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
1M ago
MRKR
Premium
Ratings
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
1M ago
MRKR
Premium
The Fly
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)
1M ago
MRKR
Premium
Pre-Earnings
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
2M ago
MRKR
Premium
Company Announcements
Marker Therapeutics Sets Date for 2026 Annual Meeting
3M ago
8K
MRKR
Premium
The Fly
Marker announces Baylor’s TACTOPS study featured on Good Morning America
3M ago
MRKR
Premium
Ratings
Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
4M ago
MRKR
Premium
The Fly
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
4M ago
MRKR
Premium
The Fly
Marker Therapeutics initiated with a Buy at H.C. Wainwright
5M ago
MRKR
Premium
Company Announcements
Marker Therapeutics Reports Q3 2025 Financial Results
5M ago
MRKR
Premium
Company Announcements
Marker Therapeutics Announces Positive APOLLO Study Results and Strategic Advances
6M ago
MRKR
Premium
The Fly
Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year
6M ago
MRKR
Premium
Company Announcements
Marker Therapeutics Strengthens Board with New Appointment
6M ago
MRKR
Premium
The Fly
Marker Therapeutics appoints Penkus Corzo to board of directors
6M ago
MRKR
Premium
Company Announcements
Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
6M ago
MRKR
Premium
Company Announcements
Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
6M ago
MRKR
Premium
Company Announcements
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
7M ago
MRKR
Premium
The Fly
Marker Therapeutics announces first patient treated in off-the-shelf program
7M ago
MRKR
Premium
Company Announcements
Marker Therapeutics Reports Promising Phase 1 Study Results
8M ago
8K
MRKR
Premium
The Fly
Marker Therapeutics provides update on observations from Phase 1 APOLLO study
8M ago
MRKR
Premium
Company Announcements
Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline
9M ago
MRKR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
